Efficacy of meropenem and amikacin combination therapy against carbapenemase-producing Klebsiella pneumoniae mouse model of pneumonia.

[1]  Taishi Tsubouchi,et al.  Molecular and epidemiological analysis of IMP-1 metallo-β-lactamase-producing Klebsiella pneumoniae in a tertiary care hospital in Japan. , 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  A. Oliver,et al.  Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. , 2017, The Lancet. Infectious diseases.

[3]  S. Rittenhouse,et al.  A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii , 2017, Journal of visualized experiments : JoVE.

[4]  M. Bassetti,et al.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. , 2015, The Journal of antimicrobial chemotherapy.

[5]  B. Gu,et al.  Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. , 2015, Journal of thoracic disease.

[6]  N. Kaku,et al.  In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  M. Niederman,et al.  A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  H. Saka,et al.  Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. , 2013, American journal of respiratory and critical care medicine.

[9]  V. Tam,et al.  Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. , 2013, The Journal of infectious diseases.

[10]  R. Bonomo,et al.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. , 2013, Diagnostic microbiology and infectious disease.

[11]  Y. Carmeli,et al.  Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  G. Daikos,et al.  Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  K. Kishi,et al.  Clinical features of healthcare‐associated pneumonia (HCAP) in a Japanese community hospital: Comparisons among nursing home‐acquired pneumonia (NHAP), HCAP other than NHAP, and community‐acquired pneumonia , 2011, Respirology.

[14]  J. Le,et al.  In Vitro Activity of Carbapenems Alone and in Combination With Amikacin Against KPC-Producing Klebsiella Pneumoniae , 2011, Journal of clinical medicine research.

[15]  N Woodford,et al.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. , 2011, The Journal of antimicrobial chemotherapy.

[16]  Y. Chuang,et al.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.

[17]  K. Bush,et al.  Hydrolysis and Inhibition Profiles of β-Lactamases from Molecular Classes A to D with Doripenem, Imipenem, and Meropenem , 2009, Antimicrobial Agents and Chemotherapy.

[18]  J. Patel,et al.  Fatal cross infection by carbapenem‐resistant Klebsiella in two liver transplant recipients , 2009, Transplant infectious disease : an official journal of the Transplantation Society.

[19]  K. Tateda,et al.  Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. , 2009, The Journal of antimicrobial chemotherapy.

[20]  Leonard Leibovici,et al.  β lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials , 2004, BMJ : British Medical Journal.

[21]  W. Craig,et al.  Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.

[22]  A. Levin,et al.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  V. Yu,et al.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. , 1999, International journal of antimicrobial agents.

[24]  J. Pechère,et al.  Efficacy of different dosing schedules of tobramycin for treating a murine Klebsiella pneumoniae bronchopneumonia. , 1987, The Journal of antimicrobial chemotherapy.